CASI Pharmaceuticals Files 6-K for July 2024
Ticker: CASIF · Form: 6-K · Filed: Jul 8, 2024 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Jul 8, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, foreign-private-issuer
Related Tickers: CASI
TL;DR
CASI Pharma (CASI) filed a 6-K on 7/8/24, updating its status as a foreign private issuer.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on July 8, 2024, reporting information for the month of July 2024. The company, previously known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023, is a foreign private issuer based in Beijing, China. The filing indicates they will file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for CASI Pharmaceuticals, Inc. as a foreign private issuer, signaling ongoing compliance and reporting activities to the SEC.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- CASI Pharmaceuticals Holdings, Inc. (company) — Former Company Name
- 20240708 (date) — Filing Date
- July 2024 (date) — Reporting Period
- 001-41666 (other) — SEC File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of July 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Has the company changed its name previously?
Yes, the company was formerly known as CASI Pharmaceuticals Holdings, Inc., with a date of name change on January 18, 2023.
Under which form will the registrant file its annual reports?
The registrant indicates it files or will file annual reports under cover of Form 20-F.
What is the SEC file number for CASI Pharmaceuticals, Inc.?
The SEC file number for CASI Pharmaceuticals, Inc. is 001-41666.
Filing Stats: 202 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-07-08 07:48:21
Filing Documents
- tmb-20240708x6k.htm (6-K) — 19KB
- tmb-20240708xex99.htm (EX-99) — 11KB
- tmb-20240708xex99001.jpg (GRAPHIC) — 10KB
- 0001962738-24-000037.txt ( ) — 45KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ Wei-Wu He Name: Wei-Wu He Title: Chairman & CEO Date: July 8, 2024